Soligenix Stock Forecast, Price & News

Soligenix (NASDAQ:SNGX) Frequently Asked Questions

Is Soligenix a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Soligenix stock.
View analyst ratings for Soligenix or view top-rated stocks.

How has Soligenix's stock been impacted by Coronavirus (COVID-19)?

Soligenix's stock was trading at $2.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SNGX shares have decreased by 68.5% and is now trading at $0.80.
View which stocks have been most impacted by COVID-19.

When is Soligenix's next earnings date?

Soligenix is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Soligenix.

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) announced its earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.03. Soligenix had a negative net margin of 945.53% and a negative trailing twelve-month return on equity of 105.58%.
View Soligenix's earnings history.

What price target have analysts set for SNGX?

2 brokerages have issued 1 year price targets for Soligenix's stock. Their forecasts range from $1.50 to $3.75. On average, they anticipate Soligenix's share price to reach $2.63 in the next year. This suggests a possible upside of 228.1% from the stock's current price.
View analysts' price targets for Soligenix or view top-rated stocks among Wall Street analysts.

Who are Soligenix's key executives?

Soligenix's management team includes the following people:

• Christopher J. Schaber, Chairman, President & Chief Executive Officer
• Jonathan L. Guarino, Chief Financial Officer, Secretary & Senior VP
• Oreola Donini, Chief Scientific Officer & Senior Vice President
• Richard C. Straube, Chief Medical Officer & Senior Vice President
• Adam T. Rumage, VP-Regulatory Affairs & Project Management

Who are some of Soligenix's key competitors?

Some companies that are related to Soligenix include OptiNose (OPTN), ProMetic Life Sciences (PFSCF), NuCana (NCNA), Tyme Technologies (TYME), Clever Leaves (CLVR), Puma Biotechnology (PBYI), Enlivex Therapeutics (ENLV), Palatin Technologies (PTN), Kazia Therapeutics (KZIA), Savara (SVRA), RedHill Biopharma (RDHL), Concert Pharmaceuticals (CNCE), Entasis Therapeutics (ETTX), Otonomy (OTIC) and Kala Pharmaceuticals (KALA).
View all of SNGX's competitors.

What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM).

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

Who are Soligenix's major shareholders?

Soligenix's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.75%), Citadel Advisors LLC (0.54%), BlackRock Inc. (0.29%), Two Sigma Securities LLC (0.15%) and Millennium Management LLC (0.07%).
View institutional ownership trends for Soligenix.

Which institutional investors are selling Soligenix stock?

SNGX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc..
View insider buying and selling activity for Soligenix or view top insider-selling stocks.

Which institutional investors are buying Soligenix stock?

SNGX stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Two Sigma Securities LLC, Geode Capital Management LLC, and Millennium Management LLC.
View insider buying and selling activity for Soligenix or or view top insider-buying stocks.

How do I buy shares of Soligenix?

Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $0.80.

How much money does Soligenix make?

Soligenix has a market capitalization of $32.08 million and generates $2.36 million in revenue each year. The biopharmaceutical company earns $-17.69 million in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does Soligenix have?

Soligenix employs 18 workers across the globe.

When was Soligenix founded?

Soligenix was founded in 1987.

What is Soligenix's official website?

The official website for Soligenix is www.soligenix.com.

Where are Soligenix's headquarters?

Soligenix is headquartered at 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at (609) 538-8200, via email at [email protected], or via fax at 609-452-6467.